S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:PRAH

PRA Health Sciences Stock Forecast, Price & News

$132.26
-2.40 (-1.78 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$130.66
Now: $132.26
$134.56
50-Day Range
$112.48
MA: $123.38
$136.53
52-Week Range
$58.67
Now: $132.26
$137.88
Volume342,200 shs
Average Volume282,736 shs
Market Capitalization$8.48 billion
P/E Ratio38.67
Dividend YieldN/A
Beta1.24
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
PRA Health Sciences logo

MarketRank

Overall MarketRank

1.46 out of 5 stars

Medical Sector

468th out of 1,923 stocks

Commercial Physical Research Industry

10th out of 42 stocks

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200
Employees17,500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.07 billion
Cash Flow$7.08 per share
Book Value$17.23 per share

Profitability

Net Income$243.02 million

Miscellaneous

Market Cap$8.48 billion
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$132.26
-2.40 (-1.78 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

How has PRA Health Sciences' stock price been impacted by COVID-19 (Coronavirus)?

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRAH shares have increased by 49.1% and is now trading at $132.26.
View which stocks have been most impacted by COVID-19
.

Is PRA Health Sciences a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRA Health Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRAH, but not buy additional shares or sell existing shares.
View analyst ratings for PRA Health Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than PRA Health Sciences?

Wall Street analysts have given PRA Health Sciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PRA Health Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Colin Shannon's approval rating as PRA Health Sciences' CEO?

500 employees have rated PRA Health Sciences CEO Colin Shannon on Glassdoor.com. Colin Shannon has an approval rating of 87% among PRA Health Sciences' employees.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for PRA Health Sciences
.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences, Inc. (NASDAQ:PRAH) announced its quarterly earnings results on Wednesday, November, 4th. The medical research company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.14 by $0.16. The medical research company earned $796.31 million during the quarter, compared to the consensus estimate of $769.14 million. PRA Health Sciences had a net margin of 7.09% and a trailing twelve-month return on equity of 22.21%. The business's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.32 EPS.
View PRA Health Sciences' earnings history
.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences updated its fourth quarter earnings guidance on Wednesday, November, 4th. The company provided earnings per share (EPS) guidance of $1.41-1.51 for the period, compared to the Thomson Reuters consensus estimate of $1.42. The company issued revenue guidance of $810-840 million, compared to the consensus revenue estimate of $818.00 million.

What price target have analysts set for PRAH?

11 Wall Street analysts have issued 12 month price objectives for PRA Health Sciences' shares. Their forecasts range from $89.00 to $145.00. On average, they anticipate PRA Health Sciences' share price to reach $110.20 in the next year. This suggests that the stock has a possible downside of 16.7%.
View analysts' price targets for PRA Health Sciences
or view Wall Street analyst' top-rated stocks.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Abbott Laboratories (ABT), The Walt Disney (DIS), PayPal (PYPL), Veeva Systems (VEEV), Pfizer (PFE) and AbbVie (ABBV).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 61, Pay $1.04M)
  • Mr. Michael J. Bonello, Exec. VP & CFO (Age 50, Pay $480.54k)
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Christopher L. Gaenzle, Exec. VP, Chief Admin. Officer, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Laurie Hurst, Sr. Director of Communications & PR
  • Ms. Tami Klerr-Naivar, Exec. VP and Chief Sales & Marketing Officer
  • Mr. Patrick R. Spine, VP of HR (Age 49)
  • Dr. Michael Kirchengast, Sr. VP of Scientific Affairs
  • Mr. David G. Passov, Sr. VP & Head of Project Management - EAPA

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pendal Group Limited (1.61%), Peregrine Capital Management LLC (0.22%), Scout Investments Inc. (0.14%), Bellecapital International Ltd. (0.08%), State of Alaska Department of Revenue (0.02%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own PRA Health Sciences stock include Christopher L Gaenzle, Colin Shannon, Fund Holdings LP Kkr and Michael J Bonello.
View institutional ownership trends for PRA Health Sciences
.

Which major investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Pendal Group Limited, Pacer Advisors Inc., and Bowling Portfolio Management LLC. Company insiders that have sold PRA Health Sciences company stock in the last year include Christopher L Gaenzle, Colin Shannon, and Michael J Bonello.
View insider buying and selling activity for PRA Health Sciences
or view top insider-selling stocks.

Which major investors are buying PRA Health Sciences stock?

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bellecapital International Ltd., Scout Investments Inc., State of Alaska Department of Revenue, International Assets Investment Management LLC, and Crossmark Global Holdings Inc..
View insider buying and selling activity for PRA Health Sciences
or or view top insider-buying stocks.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $132.26.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $8.48 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is www.prahs.com.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.